Remdesivir reduced mortality in immunocompromised patients hospitalized for COVID-19 across variant waves: Findings from routine clinical practice

Link to article at PubMed

Clin Infect Dis. 2023 Aug 9:ciad460. doi: 10.1093/cid/ciad460. Online ahead of print.


BACKGROUND: Immunocompromised patients are at high risk of severe COVID-19 and death, yet treatment strategies for immunocompromised patients hospitalized for COVID-19 reflect variations in clinical practice. This comparative effectiveness study investigated the effect of remdesivir treatment on inpatient mortality among immunocompromised patients hospitalized for COVID-19 across all variants of concern (VOC) periods.

METHODS: Data for immunocompromised patients hospitalized for COVID-19 between December 2020 and April 2022 were extracted from the US PINC AI Healthcare Database. Patients initiating remdesivir within two days of hospitalization were matched 1:1 using propensity score matching with replacement to patients who did not receive remdesivir during their hospitalization for COVID-19. Additional matching criteria included admission month, age group, and hospital. Cox Proportional Hazards models were used to examine the effect of remdesivir on risk of 14- and 28-day mortality during VOC periods.

RESULTS: A total of 19,184 remdesivir patients were matched to 11,213 non-remdesivir patients. Overall, 11.1% and 17.7% of remdesivir patients died within 14 and 28 days, respectively, compared with 15.4% and 22.4% of non-remdesivir patients. Remdesivir was associated with a reduction in mortality at 14 days (hazard ratio [95% confidence interval]: 0.70 [0.62-0.78]) and 28 days (0.75 [0.68-0.83]). Survival benefit remained significant during the Pre-Delta, Delta, and Omicron time-periods.

CONCLUSIONS: Prompt initiation of remdesivir in immunocompromised patients hospitalized for COVID-19 is associated with significant survival benefit across all variant waves. These findings provide much-needed evidence relating to the effectiveness of a foundational treatment for hospitalized COVID-19 patients among a high-risk population.

PMID:37556727 | DOI:10.1093/cid/ciad460

Leave a Reply

Your email address will not be published. Required fields are marked *